BHC - יחס חוב להיוון בספרים Valeant Pharmaceuticals

Bausch Health Companies (BHC) is a global player in the dermatology and gastroenterology segments, maintaining its position through recognizable trademarks. Management is currently optimizing the structure and reducing debt to increase capitalization, with the metric standing at 0.00. The price history on the GURU.Markets platform chart demonstrates the dynamics of an asset that partially relies on contract manufacturing and external drug distribution.

Investors use this ratio to assess creditworthiness and the degree of business reliance on borrowed funds when analyzing capital structure. The ratio of total liabilities to the book value of assets, currently 0.00, determines the financial stability of Bausch Health Companies (BHC), which supports a global production network of ophthalmology and gastroenterology drugs, a fact clearly reflected by the price action of the financial debt-to-book capital metric.